Immunogen (IMGN) surges on 'home run' ovarian cancer treatment trial data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Immunogen Inc. (IMGN) Elahere Data 'Simply Mirvelous!' - BMO
May 3, 2023 7:39 AM EDTBMO Capital analyst Etzer Darout reiterated an Outperform rating and $19.00 price target on Immunogen Inc. (NASDAQ: IMGN) following positive phase 3 data on ELAHERE. The analyst called the results "simply mirvelous!'
The analyst commented, "This morning IMGN announced that the Phase 3 MIRASOL trial studying... More
Immunogen Inc. (IMGN) PT Raised to $15 at Truist Securities on 'Home Run' Data
May 3, 2023 7:35 AM EDTTruist Securities analyst Asthika Goonewarden raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $15.00 (from $11.00) while maintaining a Buy rating, calling today's data a "home run."
The analyst commented, "We view the topline data reported this morning as a home run. MIRASOL not... More
Immunogen (IMGN) Climbs 89% After Study Shows OS Benefit in Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
May 3, 2023 7:09 AM EDTImmunogen (NASDAQ: IMGN) Climbs 89% After Study Shows OS Benefit in Phase 3 MIRASOL Trial in Patients with FR-Positive Platinum-Resistant Ovarian Cancer
Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to ChemotherapyFirst Medicine to Demonstrate an Overall Survival Advantage in... MoreImmunogen (IMGN) Reports ELAHERE Demonstrated Overall Survival Benefit in Phase 3 Trial
May 3, 2023 6:41 AM EDTImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Based on these data, the Company plans to submit a Marketing Authorization Application (MAA) in Europe and a supplemental Biologics License Application (sBLA) in the US for... More
Immunogen Inc. (IMGN) PT Raised to $11 at Truist Securities
May 2, 2023 9:14 AM EDTTruist Securities analyst Asthika Goonewarden raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $11.00 (from $10.00) while maintaining a Buy rating.... More
